Bristol-Myers Squibb Co (BMY) Receives Consensus Rating of “Hold” from Analysts

Share on StockTwits

Shares of Bristol-Myers Squibb Co (NYSE:BMY) have been assigned an average rating of “Hold” from the twenty-two ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $60.46.

BMY has been the subject of several research reports. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Morgan Stanley set a $54.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Edward Jones cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Finally, Credit Suisse Group set a $59.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, February 4th.

BMY stock traded down $0.46 during mid-day trading on Tuesday, reaching $49.64. 618,993 shares of the stock traded hands, compared to its average volume of 19,951,602. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. Bristol-Myers Squibb has a 52 week low of $44.30 and a 52 week high of $70.05. The stock has a market capitalization of $81.97 billion, a price-to-earnings ratio of 12.48, a price-to-earnings-growth ratio of 1.60 and a beta of 0.83.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 50.03%. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. During the same period in the prior year, the company earned $0.68 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Equities analysts expect that Bristol-Myers Squibb will post 4.16 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, February 1st. Investors of record on Friday, January 4th were given a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.30%. The ex-dividend date was Thursday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.

Large investors have recently bought and sold shares of the stock. Riverview Trust Co acquired a new position in Bristol-Myers Squibb in the fourth quarter worth about $33,000. Portfolio Solutions LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter worth about $37,000. Gantzert Investment Co. LLC ADV acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $39,000. 1 North Wealth Services LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $42,000. Finally, Larson Financial Group LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $64,000. 73.19% of the stock is owned by hedge funds and other institutional investors.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Story: Return On Assets

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Critical Review: COBHAM PLC/ADR  & ORIENTAL LD CO/ADR
Critical Review: COBHAM PLC/ADR & ORIENTAL LD CO/ADR
Haverty Furniture Companies  Hits New 12-Month High After Better-Than-Expected Earnings
Haverty Furniture Companies Hits New 12-Month High After Better-Than-Expected Earnings
Summit Materials  Shares Up 7.4% Following Insider Buying Activity
Summit Materials Shares Up 7.4% Following Insider Buying Activity
Ascential’s  “Buy” Rating Reaffirmed at Shore Capital
Ascential’s “Buy” Rating Reaffirmed at Shore Capital
Centrica  Downgraded to Hold at Berenberg Bank
Centrica Downgraded to Hold at Berenberg Bank
Peel Hunt Boosts Future  Price Target to GBX 660
Peel Hunt Boosts Future Price Target to GBX 660


Leave a Reply

© 2006-2019 Ticker Report